Quarterly report pursuant to Section 13 or 15(d)

Note 10 - Shareholders' Equity

v3.20.2
Note 10 - Shareholders' Equity
9 Months Ended
Sep. 30, 2020
Notes to Financial Statements  
Stockholders' Equity Note Disclosure [Text Block]
1
0
.
Shareholders' Equity
 
Authorized capital stock
 
The Company has authorized share capital of an unlimited number of voting common shares and the shares do
not
have a stated par value.
 
Common shareholders are entitled to receive dividends as declared by the Company, if any, and are entitled to
one
vote per share at the Company's annual general meeting and any special meeting.
 
Equity issued
during
the
nine
months
ended
September
30,
2020
 
On
August 10, 2020,
we issued and sold an aggregate
4,600,000
common shares in a public, underwritten offering at a public offering price of
$5.00
per share. As a result of the offering, we received gross proceeds of
$23.0
million, which resulted in net proceeds to us of approximately
$21.2
million, after deducting the underwriting discount and offering expenses.
 
On
February 13, 2020,
we issued and sold an aggregate of
2,125,000
common shares in a public, underwritten offering at a public offering price of
$4.00
per share. As a result of the offering, we received gross proceeds of
$8.5
million, which resulted in net proceeds to us of approximately
$7.7
million, after deducting the underwriting discount and offering expenses.
 
On
September 11, 2020,
we issued a warrant to purchase up to
10,000
common shares at an exercise price equal to
$4.00
per share to Craig-Hallum Capital Group LLC in consideration for certain strategic advisory services. The warrant is exercisable until
October 1, 2024,
unless terminated earlier pursuant to the terms thereof.
 
During the
nine
months ended
September 30, 2020,
7,200
common shares were issued on the exercise of options for gross proceeds of
$16,000
and
no
warrants were exercised.
 
Equity issued during the
nine
months
ended
September
30
,
2019
 
During the
nine
months ended
September 30, 2019,
50,000
common shares were issued on the exercise of options for gross proceeds of
$75,000
and
no
warrants were exercised.
 
Shares reserved
 
Common shares reserved for future issuance are as follows:
 
   
September
30, 2020
 
Stock options outstanding
   
1,395,399
 
Deferred share units outstanding
   
47,237
 
Shares available for grant under the DiaMedica Therapeutics Inc. Omnibus Incentive Plan
   
1,107,431
 
Common shares issuable under common share purchase warrants
   
265,000
 
Total
   
2,815,067